95 related articles for article (PubMed ID: 26790551)
1. Evaluation of P-glycoprotein (Pgp) expression in human osteosarcoma by high-throughput tissue microarray.
Gao Y; Liao Y; Shen JK; Feng Y; Choy E; Cote G; Harmon D; Mankin HJ; Hornicek FJ; Duan Z
J Orthop Res; 2016 Sep; 34(9):1606-12. PubMed ID: 26790551
[TBL] [Abstract][Full Text] [Related]
2. 99mTc-MIBI imaging as a predictor of therapy response in osteosarcoma compared with multidrug resistance-associated protein and P-glycoprotein expression.
Burak Z; Moretti JL; Ersoy O; Sanli U; Kantar M; Tamgac F; Basdemir G
J Nucl Med; 2003 Sep; 44(9):1394-401. PubMed ID: 12960182
[TBL] [Abstract][Full Text] [Related]
3. P-glycoprotein expression in high grade central osteosarcoma and normal bone cells. An immunohistochemical study.
Pösl M; Amling M; Grahl K; Hentz M; Ritzel H; Werner M; Winkler K; Delling G
Gen Diagn Pathol; 1997 Jun; 142(5-6):317-25. PubMed ID: 9228255
[TBL] [Abstract][Full Text] [Related]
4. The co-expression of p53 protein and P-glycoprotein is correlated to a poor prognosis in osteosarcoma.
Park YB; Kim HS; Oh JH; Lee SH
Int Orthop; 2001; 24(6):307-10. PubMed ID: 11294418
[TBL] [Abstract][Full Text] [Related]
5. Worse prognosis of osteosarcoma patients expressing IGF-1 on a tissue microarray.
Jentzsch T; Robl B; Husmann M; Bode-Lesniewska B; Fuchs B
Anticancer Res; 2014 Aug; 34(8):3881-9. PubMed ID: 25075009
[TBL] [Abstract][Full Text] [Related]
6. P-glycoprotein binds to ezrin at amino acid residues 149-242 in the FERM domain and plays a key role in the multidrug resistance of human osteosarcoma.
Brambilla D; Zamboni S; Federici C; Lugini L; Lozupone F; De Milito A; Cecchetti S; Cianfriglia M; Fais S
Int J Cancer; 2012 Jun; 130(12):2824-34. PubMed ID: 21780101
[TBL] [Abstract][Full Text] [Related]
7. Tetrandrine prevents multidrug resistance in the osteosarcoma cell line, U-2OS, by preventing Pgp overexpression through the inhibition of NF-κB signaling.
Lu Y; Li F; Xu T; Sun J
Int J Mol Med; 2017 Apr; 39(4):993-1000. PubMed ID: 28260091
[TBL] [Abstract][Full Text] [Related]
8. Association between P-glycoprotein expression and response to chemotherapy in patients with osteosarcoma: a systematic and meta-analysis.
Zhao ZG; Ding F; Liu M; Ma DZ; Zheng CK; Kan WS
J Cancer Res Ther; 2014 Nov; 10 Suppl():C206-9. PubMed ID: 25450283
[TBL] [Abstract][Full Text] [Related]
9. Immunocytochemical observation of multidrug resistance (MDR) p170 glycoprotein expression in human osteosarcoma cells. The clinical significance of MDR protein overexpression.
Bodey B; Taylor CR; Siegel SE; Kaiser HE
Anticancer Res; 1995; 15(6B):2461-8. PubMed ID: 8669809
[TBL] [Abstract][Full Text] [Related]
10. Expression of MSH2 and MSH6 on a tissue microarray in patients with osteosarcoma.
Jentzsch T; Robl B; Husmann M; Bode-Lesniewska B; Fuchs B
Anticancer Res; 2014 Dec; 34(12):6961-72. PubMed ID: 25503122
[TBL] [Abstract][Full Text] [Related]
11. The association of P-glycoprotein with response to chemotherapy and clinical outcome in patients with osteosarcoma. A meta-analysis.
Pakos EE; Ioannidis JP
Cancer; 2003 Aug; 98(3):581-9. PubMed ID: 12879476
[TBL] [Abstract][Full Text] [Related]
12. miR-15b modulates multidrug resistance in human osteosarcoma in vitro and in vivo.
Duan Z; Gao Y; Shen J; Choy E; Cote G; Harmon D; Bernstein K; Lozano-Calderon S; Mankin H; Hornicek FJ
Mol Oncol; 2017 Feb; 11(2):151-166. PubMed ID: 28145098
[TBL] [Abstract][Full Text] [Related]
13. Expression and prognostic relevance of centromere protein A in primary osteosarcoma.
Gu XM; Fu J; Feng XJ; Huang X; Wang SM; Chen XF; Zhu MH; Zhang SH
Pathol Res Pract; 2014 Apr; 210(4):228-33. PubMed ID: 24440098
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of tumor suppressors in osteosarcoma before and after neoadjuvant chemotherapy.
Robl B; Pauli C; Botter SM; Bode-Lesniewska B; Fuchs B
BMC Cancer; 2015 May; 15():379. PubMed ID: 25956431
[TBL] [Abstract][Full Text] [Related]
15. P16 expression predicts necrotic response among patients with osteosarcoma receiving neoadjuvant chemotherapy.
Borys D; Canter RJ; Hoch B; Martinez SR; Tamurian RM; Murphy B; Bishop JW; Horvai A
Hum Pathol; 2012 Nov; 43(11):1948-54. PubMed ID: 22578565
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of blood and urinary angiogenic factor levels at diagnosis and during treatment in patients with osteosarcoma: a prospective study.
Tabone MD; Brugières L; Piperno-Neumann S; Selva MA; Marec-Bérard P; Pacquement H; Lervat C; Corradini N; Gentet JC; Couderc R; Chevance A; Mahier-Ait Oukhatar C; Entz-Werle N; Blay JY; Le Deley MC
BMC Cancer; 2017 Jun; 17(1):419. PubMed ID: 28619014
[TBL] [Abstract][Full Text] [Related]
17. Clinical and biological significance of PIM1 kinase in osteosarcoma.
Liao Y; Feng Y; Shen J; Gao Y; Cote G; Choy E; Harmon D; Mankin H; Hornicek F; Duan Z
J Orthop Res; 2016 Jul; 34(7):1185-94. PubMed ID: 26687194
[TBL] [Abstract][Full Text] [Related]
18. Interferon-α/β receptor as a prognostic marker in osteosarcoma.
Kubo T; Shimose S; Matsuo T; Fujimori J; Arihiro K; Ochi M
J Bone Joint Surg Am; 2011 Mar; 93(6):519-26. PubMed ID: 21411701
[TBL] [Abstract][Full Text] [Related]
19. pFAK-Y397 overexpression as both a prognostic and a predictive biomarker for patients with metastatic osteosarcoma.
Thanapprapasr K; Nartthanarung A; Thanapprapasr D; Jinawath A
PLoS One; 2017; 12(8):e0182989. PubMed ID: 28846700
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of P-glycoprotein, HER-2/ErbB-2, p53, and Bcl-2 in primary tumor and metachronous lung metastases in patients with high-grade osteosarcoma.
Ferrari S; Bertoni F; Zanella L; Setola E; Bacchini P; Alberghini M; Versari M; Bacci G
Cancer; 2004 May; 100(9):1936-42. PubMed ID: 15112275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
